A Johnson & Johnson subsidiary agrees to pay $181 million to settle dozens of states' claims that it engaged in illegal off-label marketing of antipsychotic drugs, with New Jersey to receive $5.3 million.
August 30, 2012 at 11:20 PM
1 minute read
A Johnson & Johnson unit agreed Thursday to pay $181 million to settle dozens of states’ claims that it engaged in illegal off-label marketing of antipsychotic drugs, with New Jersey to receive $5.3 million.
Janssen Pharmaceuticals Inc. of Titusville improperly marketed Risperdal, Risperdal Consta, Risperdal M-Tab and Invega, in violation of federal law, according to Chiesa v. Janssen Pharmaceuticals, MER-C-75-12.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
